Literature DB >> 17641866

[Molecular principles of alternative treatment approaches for hormone-refractory prostate cancer].

P Thelen1, P Burfeind, S Schweyer, J-G Scharf, W Wuttke, R-H Ringert.   

Abstract

Prostate cancer is more frequently diagnosed in men from Western countries than from Asian societies. Therefore, nutritional factors such as phyto-oestrogens from soya are considered to cause this prostate cancer prevention effect. As there is no curative therapy for hormone-refractory prostate cancer, new strategies are in demand which might include phyto-oestrogens or inhibitors of histone deacetylases. Both approaches have in common the potential to reduce the aberrant androgen receptor and IGF receptor signalling. Furthermore, invasiveness and acquired survival strategies of tumours can be diminished. Reduced tumour cell proliferation and PSA secretion coincide with altered gene expression in the aforementioned processes. In addition, selective knock-down of genes by RNA interference afforded functional analyses regarding impact and succession of expression events involved in the beneficial effects caused by phyto-oestrogens and histone deacetylase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641866     DOI: 10.1007/s00120-007-1452-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  9 in total

Review 1.  Dietary isoflavones: biological effects and relevance to human health.

Authors:  K D Setchell; A Cassidy
Journal:  J Nutr       Date:  1999-03       Impact factor: 4.798

Review 2.  Prostate cancer chemoprevention by silibinin: bench to bedside.

Authors:  Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

Review 3.  Cancer chemoprevention with dietary phytochemicals.

Authors:  Young-Joon Surh
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 4.  Unconventional therapy for prostate cancer: good, bad or questionable?

Authors:  Peter S Nelson; Bruce Montgomery
Journal:  Nat Rev Cancer       Date:  2003-11       Impact factor: 60.716

Review 5.  Impact of diet on prostate cancer: a review.

Authors:  G A Sonn; W Aronson; M S Litwin
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

6.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.

Authors:  Giles O Hellawell; Gareth D H Turner; David R Davies; Richard Poulsom; Simon F Brewster; Valentine M Macaulay
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

Review 7.  Drug insight: role of the androgen receptor in the development and progression of prostate cancer.

Authors:  Mary-Ellen Taplin
Journal:  Nat Clin Pract Oncol       Date:  2007-04

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

  9 in total
  1 in total

Review 1.  The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.

Authors:  Andrea Dueregger; Isabel Heidegger; Philipp Ofer; Bernhard Perktold; Reinhold Ramoner; Helmut Klocker; Iris E Eder
Journal:  Nutrients       Date:  2014-10-21       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.